Compare MWG & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWG | BIAF |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | 57 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 4.6M |
| IPO Year | 2022 | N/A |
| Metric | MWG | BIAF |
|---|---|---|
| Price | $1.36 | $1.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.4K | ★ 319.7K |
| Earning Date | 06-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.23 |
| 52 Week High | $2.49 | $13.50 |
| Indicator | MWG | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 31.61 | 32.56 |
| Support Level | $0.23 | $1.23 |
| Resistance Level | $2.20 | $1.79 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 6.45 | 20.37 |
Multi Ways Holdings Ltd is a supplier of a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region. The wide variety of new and used heavy construction equipment for sale and rental by customers range from: earth-moving equipment such as bulldozers, off-terrain dump trucks, excavators and wheel loaders; material-handling equipment such as crawler cranes, rough terrain cranes, scissor lifts, forklifts, boom-lifts and telescopic handlers; road-building equipment such as motor graders, vibrating compactors, asphalt finishers, skid loaders, backhoe loaders, hand rollers and mini excavators; and generators and compressors, such as air compressors, generators, lighting towers and welding machines.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.